Boston Scientific Corporation $BSX Shares Bought by Gladstone Institutional Advisory LLC

Gladstone Institutional Advisory LLC lifted its holdings in Boston Scientific Corporation (NYSE:BSX) by 39.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 51,884 shares of the medical equipment provider’s stock after acquiring an additional 14,700 shares during the quarter. Gladstone Institutional Advisory LLC’s holdings in Boston Scientific were worth $5,065,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Riverwater Partners LLC grew its position in Boston Scientific by 3.3% in the second quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock worth $333,000 after buying an additional 98 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management boosted its stake in shares of Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock worth $291,000 after acquiring an additional 99 shares in the last quarter. Crown Wealth Group LLC raised its position in shares of Boston Scientific by 4.7% during the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after purchasing an additional 100 shares during the period. IVC Wealth Advisors LLC raised its position in shares of Boston Scientific by 4.9% during the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock worth $236,000 after purchasing an additional 102 shares during the period. Finally, Sound View Wealth Advisors Group LLC lifted its holdings in shares of Boston Scientific by 3.9% during the second quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock valued at $294,000 after purchasing an additional 103 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Activity at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the sale, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 93,095 shares of company stock valued at $9,305,450. Corporate insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Wells Fargo & Company lifted their price target on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Cowen reissued a “buy” rating on shares of Boston Scientific in a research note on Thursday, December 11th. BTIG Research reissued a “buy” rating and set a $132.00 price target on shares of Boston Scientific in a research report on Friday, November 21st. The Goldman Sachs Group restated a “buy” rating and set a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, October 22nd. Finally, Canaccord Genuity Group lowered their target price on Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a research note on Wednesday, December 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $124.95.

Boston Scientific Trading Up 0.9%

NYSE:BSX opened at $95.54 on Tuesday. The company has a market capitalization of $141.63 billion, a P/E ratio of 51.09, a P/E/G ratio of 1.68 and a beta of 0.67. The stock’s 50 day moving average price is $97.78 and its 200 day moving average price is $100.87. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same period in the previous year, the firm posted $0.63 earnings per share. The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.